an earlier keiretsu round in immunomic therapeutics

LAMP-vax

Sector
Biotechnology / Vaccine Platform
headquarters
Rockville, Maryland, USA
Stage
Platform licensing round
$3.2M
Reported Keiretsu investment in this round
4.4x
Reported return on this tranche
$300M
Astellas licence covering the LAMP-vax platform

LAMP-vax is Immunomic Therapeutics’ own allergy vaccine platform, and Keiretsu Forum tracks a $3.2M investment and 4.4x return against it as a distinct round resolved by the same October 2015 Astellas licence.

A separately reported Keiretsu round in Immunomic, not a separate company

Laboratory work on the LAMP-vax allergy vaccine platform

01

An important clarification

LAMP-vax is not a separate company from Immunomic Therapeutics — it is Immunomic’s own core vaccine platform, and the $300M Astellas licensing deal referenced here is the identical October 2015 transaction described in the Immunomic Therapeutics case study. This entry exists because Keiretsu Forum’s own reporting tracks the relationship as two separate line items, plausibly because different chapters, or different funding rounds, each report their own investment amount and return multiple against the same eventual outcome.

02

What the facts support

The underlying facts are shared with the Immunomic profile: Immunomic Therapeutics licensed its Johns Hopkins-originated LAMP technology in 2006, developed it into the LAMP-vax allergy vaccine platform, and signed a worldwide licensing agreement with Astellas Pharma in October 2015 valued at $300 million in upfront and milestone payments plus double-digit royalties. Keiretsu Forum’s Mid-Atlantic, Northwest and Vancouver chapters are documented as investors in the company across its funding history — consistent with a $3.2 million figure representing one or more specific rounds rather than the company’s total lifetime fundraising.

03

The journey

A $3.2 million investment producing a 4.4x return, and a separately reported 45x return on Immunomic overall, are not necessarily contradictory: they could reflect two different tranches of capital invested at two different valuations and dates, both resolved by the same licensing event. If the 4.4x figure reflects a later, closer-to-exit round, it would rationally show a lower multiple than an earlier round — later investors typically buy in at a higher valuation and therefore see a smaller multiple on the same outcome, which is a plausible and internally consistent explanation for why both numbers could be accurate at once.

Read this entry as a distinct Keiretsu Forum round in Immunomic Therapeutics rather than as a second, unrelated $300M pharma licensing deal. Neither the $3.2 million investment nor the 4.4x return is independently verifiable in public sources; both trace back to Keiretsu Forum’s internal reporting. The Astellas licence itself is well documented in the trade press.

  1. 2006

    LAMP technology licensed from Johns Hopkins

  2. 2013 - 2015

    Keiretsu chapters invest across rounds

  3. October 2015

    Worldwide LAMP-vax licence to Astellas

  4. Post-licence

    Reported 4.4x return on this tranche

04

The outcome

The Astellas agreement covered LAMP-vax products for allergic disease worldwide, while Immunomic retained the rights to apply the LAMP platform to other indications including cancer immunotherapy. No sale of the company and no IPO was required for investors in this round to realise a return — the licensing deal itself was the liquidity event, and Immunomic remained independent afterwards.

05

Network Impact

Whether read as a single entry or two, the impact story is the same as the Immunomic Therapeutics profile: distributed, patient angel capital across multiple Keiretsu Forum chapters carried a platform technology through its highest-uncertainty period, until a major pharmaceutical partner was willing to pay to validate it.

What this entry adds is a view of the same outcome from a different point on the capital timeline — a reminder that a single portfolio company can produce very different return multiples for members depending on which round they joined.

06

Sources

Building the next great company?

Whether you’re raising capital or looking for your next investment opportunity, connect with Keiretsu Forum MENA.

Apply as a Startup